Document is current
Any future updates will be listed below
-
Authors
Koerber, Julia
Javanbakht, Marjan
Setrakian, Naira
Chung, Un Young Rebecca
Akabike, Whitney N.
Dardick, Lawrence
Cooper, Ziva D.
Gelberg, Lillian
-
Funding
Funding for this research was provided by:
University of California Tobacco-Related Disease Research Program (T29IR0277)
California Department of Cannabis Control (DCC 93308)
University of California Tobacco-Related Disease Research ProgramUniversity of California Tobacco-Related Disease Research Program (T29IR0277)
- License Information
-
More Information
Article History
Received: 23 July 2025
Accepted: 29 October 2025
First Online: 29 December 2025
Declarations
:
: This is a secondary analysis of deidentified electronic medical records that was conducted in accordance with the US Department of Health and Human Services Office for Human Research Protections Common Rule and the Declaration of Helsinki. The Institutional Review Board (IRB) at the University of California, Los Angeles reviewed and approved this project, waiving consent. This IRB ethics committee determined that the research from this project offered no more than minimal risks to patients. Because of the number of patients in this study, collecting informed consent would have been impractical, and waiving informed consent for this project was determined to not negatively impact patients’ rights and welfare. Clinical trial number: not applicable.
: Not applicable.
: The authors declare that they have no competing interests or disclosures with this publication. Outside of this work, JK received NIH National Institute of Drug Abuse R36 Dissertation award R36DA060098-01. Outside of this work, ZDC reports receiving study drug from Canopy Growth Corp and True Terpenes, and study-related materials from Storz & Bickel.
